Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis

NCT05660382 | Completed Phase 3 Results FDA Drug

• 1 other identifier: MZ-1015-ESP3-054
• Study Type: interventional
• Target: 112
• Locations: 1 country
• Sites: 7

Brief Summary

The goal of this clinical trial is to prove the that miconazole oil works well on fungal infections of the ears, by comparing the drug with a placebo. The researcher or the participants will not know if they are getting the drug or the placebo. The researcher will show the participants how to use the drug or placebo. After 14 days of using the drug or placebo, the participants will be examined by the researcher and graded on how well the drug worked on the ear(s) fungal infection. Participants will also be checked and asked for any bad side effects from the drug or the placebo.

Conditions

Otomycosis

Outcome Measures

Primary Outcomes (1)

• Clinical Cure

  A score of 0 for fungal elements, pruritus, debris, and aural fullness

  7 days after 14 days of Treatment

Study Arms (2)

Active group

ACTIVE COMPARATOR

Miconazole (2%) oil, administered as 5 drops per ear at \~30 mg per drop instilled into the external ear canal of the ear(s) affected by otomycosis, twice daily for 14 days.

Drug: Miconazole (2%) oil and mineral oil

Placebo group

PLACEBO COMPARATOR

Mineral oil, administered as 5 drops per ear instilled into the external ear canal of the ear(s) affected by otomycosis, twice daily for 14 days.

Other: Placebo

Interventions

Miconazole (2%) oil and mineral oil DRUG

Twice daily application, for 14 days.

Also known as: Miconazole oil

Active group

Placebo OTHER

Twice daily application, for 14 days

Also known as: Mineral oil

Placebo group

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or non-pregnant, non-lactating females
• Diagnosis of uncomplicated otomycosis of the external ear only, in the ear(s) that will be treated with study drug, with a score for fungal elements of 1 in each ear to be treated with study drug (see Section 7.4 for definitions of the scores for each of the otomycosis signs and symptoms). Subjects must also have the following signs and symptoms of otomycosis in the study ear: pruritus ≥2; debris ≥2; and aural fullness ≥2.
• General good health as determined by medical examination and medical history, and who are free of clinically significant disease, including diabetes mellitus that is not well-controlled or that could interfere with the study
• Females of childbearing potential must have had a negative urine pregnancy test at Screening/Baseline and must agree to use an effective method of contraception (as defined in Section 8.5) from Screening/Baseline up through the End of Treatment visit (see Section 6). Females of childbearing potential include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea \>12 consecutive months). Females who are using oral, implanted, or injectable contraceptive hormones, an intrauterine device (IUD), barrier methods (diaphragm, condoms, spermicide) to prevent pregnancy, practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of childbearing potential
• Subjects and/or their caregivers (as appropriate for the age of the subject) must have full legal capacity to volunteer
• Subjects and/or their caregivers must have completed an appropriately administered institutional review board (IRB)-approved informed consent and assent (as applicable) prior to any study related procedures
• Subjects and their caregivers (as applicable) must agree to comply with all requirements of the protocol
• For subjects with only one ear meeting all study eligibility criteria, the subject will be eligible for the study, and the ear meeting all eligibility criteria will be treated with study drug and considered to be the study ear for the purposes of study evaluations. In case of bilateral otomycosis in which at least one ear meet all study eligibility criteria, the subject will be eligible for the study, both ears may be treated with study drug provided that both ears have a score of 1 for fungal elements, and the worse ear will be considered to be the study ear for the purposes of study evaluations. If both ears meet study eligibility criteria and are determined by the investigator to have the same degree of infection at Screening/Baseline, the left ear will be considered to be the study ear for the purposes of study evaluations.

You may not qualify if:

• Any other dermatoses or conditions of the ear that may interfere with the evaluation of otomycosis, including concomitant otic infections (including bacterial infection) that require antimicrobial treatment, disease that has spread beyond the external ear(s), or pre-existing skin atrophy of the affected ear(s) that will be treated with study drug
• Tympanostomy tube or perforated tympanic membrane in the ear(s) that will be treated with study drug
• History of prior surgery directly affecting and compromising the external auditory canal and/or tympanic membrane of the ear(s) that will be treated with study drug, except for prior tympanostomy tube(s) that have already been removed and completely healed
• Use of any topical medicated treatments for otomycosis within 14 days of study entry for the ear(s) that will be treated with study drug
• Use of any systemic antifungal therapy within 28 days of study entry, warfarin within 28 days of study entry, immunosuppressive or immune-stimulating drugs within 28 days of study entry, or systemic steroids within 3 months of study entry
• Fever of ≥100°F at study entry
• Recurrent otomycosis that has been unresponsive to previous antifungal treatment within the last 12 months
• Known hypersensitivity to any of the components in the test formulation
• Participation in another investigative trial within 28 days of study entry.

Sponsors & Collaborators

• Hill Dermaceuticals, Inc.: lead

Study Sites (7)

Head and Neck Surgery Specialist

Chula Vista, California, 91910, United States

Location

Advanced ENT & Allergy

Louisville, Kentucky, 40220, United States

Location

Charleston ENT Associates, LLC

North Charleston, South Carolina, 29406, United States

Location

Carolina ENT

Orangeburg, South Carolina, 29118, United States

Location

Spartanburg / Greer ENT & Allergy

Spartanburg, South Carolina, 29303, United States

Location

Alamo ENT Associates

San Antonio, Texas, 78258, United States

Location

ENT Center Of Utah

Salt Lake City, Utah, 84102, United States

Location

MeSH Terms

Conditions

Otomycosis

Interventions

Miconazole; Oils; Mineral Oil

Condition Hierarchy (Ancestors)

Mycoses; Bacterial Infections and Mycoses; Infections; Ear Diseases; Otorhinolaryngologic Diseases

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Lipids; Petrolatum; Hydrocarbons; Organic Chemicals

Results Point of Contact

• Title: Gerardo Mendez
• Organization: Hill Dermaceuticals, Inc.

gerardo.mendez@hillderm.com

407-323-1887

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Masking for participants, care providers, Investigators, outcome assessors
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Participants are assigned to one of two groups in parallel for the duration of the study

Study Record Dates

• First Submitted: December 13, 2022
• First Posted: December 21, 2022
• Study Start: March 2, 2023
• Primary Completion: December 27, 2024
• Study Completion: December 27, 2024
• Last Updated: April 20, 2026
• Results First Posted: April 20, 2026

Record last verified: 2026-03

Locations

US (7)